Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2020-01-16 Transaction in Own Shar…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Updates
Transaction in Own Shares Classification · 95% confidence The document contains a table listing names of transferors and transferees along with the number of equity shares transferred on a specific date (13.01.2020). This indicates it is reporting transactions involving the company's own shares, specifically share transfers between parties. There is no indication of a broader financial report, regulatory filing, or announcement of voting results. The content aligns with reporting of transactions in own shares (share repurchases or transfers). Therefore, the document is best classified as a Transaction in Own Shares (POS). The document length is short but contains substantive data about share transactions, not just an announcement or certification.
2020-01-16 English
In compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. SEBI/HO/MIRSD/DOS3/CIR/P
Major Shareholding Notification Classification · 95% confidence The document is a disclosure regarding the transfer of shares as per a SEBI circular, listing names of transferors and transferees along with the number of shares transferred. It references compliance with SEBI Listing Regulations and a specific SEBI circular dated November 6, 2018. The content is focused on share transfer details and does not contain financial statements, management discussion, or other report content. The document length is 3863 characters, which is relatively short and primarily an announcement of share transfers. This fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels or share transfers. Therefore, the appropriate classification is MRQ with high confidence.
2020-01-16 English
Morepen Laboratories Ltd has informed BSE regarding Issuance of Duplicate share Certificates by the Company
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates. It references Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about a specific administrative action related to share certificates, not a financial report, earnings release, or management discussion. The document length is short (2749 characters) and it is an official notification to the exchanges about duplicate share certificates issued. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into other specific categories like share issue or capital change (SHA) or director dealings (DIRS).
2020-01-14 English
Morepen Laboratories Ltd has informed BSE regarding Issuance of Duplicate share Certificates and loss of Share Certificates of the Company.
Share Issue/Capital Change Classification · 95% confidence The document is an official communication addressed to stock exchanges (National Stock Exchange of India Ltd. and BSE Limited) regarding the issuance of duplicate share certificates and the loss of share certificates. It references Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content includes details about specific share certificates being duplicated or reported lost, and it is a notification rather than a financial report or detailed analysis. The document length is 4176 characters, which is relatively short and primarily serves as an announcement or intimation to the stock exchanges about share certificate issues. This fits the category of Share Issue/Capital Change (SHA), as it relates to changes in share certificates and capital documentation rather than financial results, management changes, or regulatory filings of other types.
2020-01-07 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure made by Morepen Laboratories Limited to stock exchanges (NSE and BSE) regarding defaults on payment of interest and repayment of principal on loans and unlisted debt securities, specifically Compulsory Redeemable Preference Shares (CRPS). It references a SEBI circular dated November 21, 2019, which mandates such disclosures. The content includes detailed tables of default amounts, dates, and investor information. This type of disclosure is a regulatory compliance filing related to financial indebtedness and default status, not a full financial report or earnings release. It is not an annual or interim report, audit report, or earnings release. It is a regulatory announcement about defaults on debt obligations as required by SEBI. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-01-06 English
Pursuant to SEBI Circular no. SEBI/HO/CFD/CMD1/CIR/P/2019/140 dated November 21, 2019, please find attached herewith disclosure for defaults in redemption of Compulsory Redeemable Preference ....
Regulatory Filings Classification · 95% confidence The document is a disclosure related to defaults on payment of interest and repayment of principal on loans and unlisted debt securities, specifically Compulsory Redeemable Preference Shares (CRPS). It references a SEBI circular dated November 21, 2019, and provides detailed financial information about defaults, amounts outstanding, and terms of the debt instruments. The document is addressed to stock exchanges and includes tables with financial data but does not contain comprehensive financial statements or a full financial report. It is a regulatory disclosure about financial indebtedness and defaults rather than a full annual or interim report, earnings release, or audit report. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2020-01-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.